AstraZeneca stock price forecast: bullish momentum and earnings support as AZN stays above £13,700

Traders Union
All News
Financial News
AstraZeneca rises 0.29% to GBX 13,790

Highlights

AstraZeneca reported quarterly earnings per share of $1.19 and revenue of $15.19 billion, both exceeding consensus estimates.
The company announced a C$820 million (US$570 million) investment in Canada to advance its clinical pipeline, supported by a C$16.1 million government contribution.
Institutional investors Moody Lynn & Lieberson LLC and Ethic Inc. increased their positions in AstraZeneca, signaling heightened institutional interest.

Earnings beat and pipeline expansion drive institutional accumulation

AstraZeneca reported quarterly earnings with earnings per share of $1.19 and revenue of $15.19 billion, both surpassing consensus estimates. The company further enhanced its clinical pipeline by announcing a C$820 million (US$570 million) investment in Canada, supported by a C$16.1 million government contribution. Institutional interest was evident as Moody Lynn & Lieberson LLC and Ethic Inc. increased their positions in AstraZeneca.

Momentum signals support upside as buyers test overbought territory

Momentum indicators remain positive, with MACD and ADX both delivering a buy or strong buy signal, supported by RSI levels that suggest further upside potential without overbought risk. Meanwhile, Stoch RSI and Bull/Bear Power (BBP) indicate overbought conditions, highlighting strong buyer dominance that could limit near-term gains. The latest price is near today's high of GBX 13,844.00 within an intraday range of GBX 13,722.00 to GBX 13,844.00, with moderate volatility and price action consistently trending toward session highs.

Sideways range anticipated with bullish tilt on strong technical signals

For the upcoming week, the expected price range is GBX 13,500.00 to GBX 13,900.00, reflecting typical volatility at current levels. The technical outlook favors a sideways trade between these bands, with an over 80% probability of an upward move based on synchronized weekly buy signals. A bullish breakout requires a close above GBX 13,900.00 for further highs, while a reversal scenario would be triggered by sustained trading below GBX 13,500.00.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca’s technical setup as supportive but notes that overbought signals and crowded sentiment warrant caution. He believes strong earnings and institutional buying offer a positive backdrop, though the stock now faces clear resistance near GBX 13,900.00. Tactical bias is sideways unless price sustains above or below key levels. "Until AstraZeneca closes decisively above GBX 13,900.00, I remain neutral and watch for possible retracements from overbought territory."

Previously it was reported that AstraZeneca PLC is exhibiting bullish momentum, trading above its key moving averages with strong MACD and ADX signals reinforcing the uptrend. However, overbought readings from momentum oscillators suggest the stock may consolidate within a range between GBX 13,400 support and GBX 14,200 resistance, with a potential breakout dependent on clearing the upper boundary.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.